An observational study in Asthma, sponsored by Region Skane. Completed at 1 site in Sweden. Open to participants aged 18 Years to 80 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-05.
Sponsored by Region Skane · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 93 studies in Asthma with a site in Sweden — 6 open to participants now, 11 under way, none of them phase 3. Asthma · Sweden.
Among the 93 studies in Asthma with a site in Sweden, this one is the 12th largest by enrollment of the 12 observational ones that give a count, is one of 4 that started in 2019, is one of 12 observational ones, and was the 83rd registered.
4,850 studies on the registry are indexed under Asthma; 604 are open to participants now.
Browse Asthma studies →6 of the 93 studies in Asthma with a site in Sweden are open now. Recruiting first, the newest first:
Karolinska Institutet · Sites in Sweden
Ages 18–50
Region Skane · Sites in Sweden
Ages 18+
Windward Bio · Sites in Sweden, United States, Argentina and 5 more countries
Ages 18–75
Karolinska Institutet · Sites in Sweden
Ages 16+
St. Olavs Hospital · Sites in Sweden, Finland, Norway
Ages 3 mo–23 mo
A study can be open while its sites in Sweden have not opened yet or have stopped. Only those recruiting at a site in Sweden →
Of the 416 Asthma studies recruiting now, 141 (34%) set no upper age limit and 204 (49%) stop at 75 or younger; 146 take children under 18; 105 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
93 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 24 · Phase 3 21 · Phase 4 15
First in 1987; this study’s year is marked. 4 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 37 is below the median of 159 across 1,254 observational studies indexed under Asthma.
Median enrollment 134 across the 81 interventional studies, 1,231 across the 12 observational. Of the 80 that completed or were terminated, 34 (43%) have results posted.
This tab as a report to print or save as PDF → With an account.
64 of 93 have an industry lead sponsor. The 10 most frequent:
Region Skane is the lead sponsor of 386 studies on the registry; 122 are open to participants now.
Region Skane has 2 studies filed under Asthma — fewer than ten, so there is no comparison to draw.
5 of the studies in Asthma with a site in Sweden that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06657807Karolinska InstitutetOnline Cognitive Behavior Therapy for Anxiety Related to Pediatric Asthma | 2026-12 |
| NCT07500974Region SkaneEfficacy of L-menthol on Breathlessness in Asthma | 2027-04 |
| NCT07145632Karolinska InstitutetAPP-based Medical Device for Education and Training of Inhalation Technique | 2027-06-01 |
| NCT06676319SanofiStudy of Lunsekimig (SAR443765) Compared With Placebo in Adults With High-risk Asthma | 2027-06-21 |
| NCT07651891Karolinska InstitutetEvaluation of ALLERgen Specific Vaccination of DOG Allergic Patients in Swedish Practice | 2027-10-01 |
Add all 5 to your calendar (.ics) → With an account.
Among the 93 studies in Asthma with a site in Sweden, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this exploratory and observational prospective study is to study the composition and phenotypes of blood leukocytes collected from asthmatic patients before and after instantiated treatment with the interleukin-5 neutralizing antibody mepolizumab. Comparisons will be made to leukocyte profiles in patients already on mepolizumab treatment, asthma patients without any biological treatment, and non-diseased control subjects.
Asthma is a chronic inflammatory and obstructive condition affecting the airways. The disease is commonly associated with elevated blood eosinophils and tissue eosinophilia. Many aspects of the pathophysiological mechanisms and clinical symptoms are controlled by conventional therapies such as inhaled corticosteroids (ICS) and long acting β2 agonists. However, some patients remain clinically uncontrolled and need additional treatment such as direct targeting of eosinophil granulocytes by neutralizing the eosinophil-promoting cytokine interleukin 5 (IL5). Mepolizumab is a humanized monoclonal IL-5 neutralizing antibody that is used to treat patients with moderate-severe eosinophilic asthma. While a marked reduction of eosinophils is a key effect of mepolizumab, the exact mechanism of action is unknown. Apart from basophils, that also express the receptor for IL-5, other leukocytes are likely to be indirectly affected by the suppressed eosinophilia. In addition, it is largely unknown to what extent the few eosinophils remaining after anti-IL5 treatment differ from pre-treatment eosinophils.
The present study is a prospective observational asthma study that aims to use microscopic analysis to investigate the composition and subtypes of blood leukocytes collected before and after instantiated mepolizumab treatment. Comparisons are made to patients already on mepolizumab treatment, asthma patients without any biological treatment, and non-diseased control subjects.
All asthma patients will be recruited at the Department of Allergology and Lung Medicine, Skåne University Hospital (SUS), Lund, Sweden. Healthy control subjects are recruited by local advertisement.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion criteria:
Patients will be selected on the standard criteria used to select eligible asthma patients for mepolizumab treatment (i.e. patients with eosinophilic asthma that are not controlled by conventional high dose ICS and LABA etc). All eligible asthma patients may be included. Exclusion criteria: any infection
Biological: Mepolizumab · Drug: Standard inhaled corticosteroids (ICS) and long-acting beta 2 agonists (LABA)
Patients that have been selected and given Mepolizumab treatment for \> 4 months according to standard eligible and treatment regimen criteria (i.e. patients with eosinophilic asthma that are not controlled by conventional high dose ICS and LABA etc). All eligible asthma patients that have been on Mepolizumab treatment for \> 4 weeks will be included. Exclusion criteria: any infections
Biological: Mepolizumab · Drug: Standard inhaled corticosteroids (ICS) and long-acting beta 2 agonists (LABA)
Inclusion: Asthma patients without any biological (antibody-based) treatment but on routine ICS and LABA treatment as part of their normal care. Exclusion criteria are any infections
Drug: Standard inhaled corticosteroids (ICS) and long-acting beta 2 agonists (LABA)
Exclusion criteria: previous history of lung disease, chronic inflammatory condition, or atopy, or cardiovascular disease. Diagnosed or perceived infection within 3 weeks prior to blood sampling
Mepolizumab is administered by subcutaneous injection with guideline recommended patient selection and dosing for treatment of eosinophilic asthma. Accordingly, the Mepolizumab treatment is given as add-on therapy to standard inhaled corticosteroids (ICS) and long-acting beta 2 agonists (LABA)
Also known as: Mepolizumab (brand name: Nucala)
Routine asthma treatment with inhaled corticosteroids (ICS) and long-acting beta 2 agonists (LABA)
Also known as: ICS and LABA
Change in Blood Eosinophil Marker Expression
Quantitative analysis of low-intensity proMBP-positive eosinophil-lineage proxy cells in FFPE blood leukocyte pellet sections
Time frame: Baseline, Day 2, and Month 4 after mepolizumab initiation
Change in Blood Basophil Marker Expression
Quantitative analysis of high-intensity proMBP-positive basophil-like cells in FFPE blood leukocyte pellet sections.
Time frame: Baseline, Day 2, and Month 4 after mepolizumab initiation
Change in Blood Leukocyte Composition
Relative proportion of low-/mid-intensity proMBP-positive eosinophil-lineage proxy cells within the proMBP panel in FFPE blood leukocyte pellet sections
Time frame: Baseline, Day 2, and Month 4 after mepolizumab initiation
Change in Blood T Lymphocyte Marker Expression
Quantitative CD4 Th-axis balance readout in FFPE blood leukocyte pellet sections, expressed as log2(GATA3/T-bet ratio).
Time frame: Baseline, Day 2, and Month 4 after mepolizumab initiation
Change in Blood B Lymphocyte Marker Expression
Quantitative B-cell HLA-DR readout in FFPE blood leukocyte pellet sections, expressed as the percentage of HLA-DR-positive cells within the CD19/CD20-gated population.
Time frame: Baseline, Day 2, and Month 4 after mepolizumab initiation
Leukocyte Total Cell Counts
Routine clinical laboratory total leukocyte counts in peripheral blood
Time frame: Baseline, Day 2, and Month 4 after mepolizumab initiation.
Change in Forced Expiratory Volume in 1 Second (FEV1)
Spirometry: Forced Expiratory Volume, 1s; (FEV1).
Time frame: Change from baseline at 4 weeks, and 4 months after initiated biological treatment.
Change in Forced Vital Capacity (FVC)
Spirometry: Forced Vital Capacity (FVC)
Time frame: Change from baseline at 4 weeks, and 4 months after initiated biological treatment.
Change in Exhaled FeNo
Fractional exhaled NO will be measured at multiple flows
Time frame: Before and 1-3 days, 1 week, 4 weeks, and 4 months after initiated biological treatment.
Recruitment and follow-up were substantially affected by COVID-19-related restrictions and post-pandemic delays in restarting clinical research. In addition, clinical use of mepolizumab decreased over time as other biologics for type 2-high asthma became more commonly used. These factors reduced the number of eligible mepolizumab initiators during the study period.
| Milestone | Group 1: T2-high Asthma Initiating Mepolizumab | Group 2: T2-high Asthma on Maintenance Mepolizumab | Group 3: Moderate-severe Asthma Not Eligible for Biologics | Group 4: Healthy Controls |
|---|---|---|---|---|
| Started | 5 | 10 | 11 | 11 |
| Completed | 5 | 10 | 11 | 11 |
| Not completed | 0 | 0 | 0 | 0 |
Quantitative analysis of low-intensity proMBP-positive eosinophil-lineage proxy cells in FFPE blood leukocyte pellet sections
| Cells per section | Group 1: T2-high Asthma Initiating Mepolizumab | Group 2: T2-high Asthma on Maintenance Mepolizumab | Group 3: Moderate-severe Asthma Not Eligible for Biologics | Group 4: Healthy Controls |
|---|---|---|---|---|
| Baseline | 274.8 (74 to 490) | — | — | — |
| Day 2 | 48.6 (12 to 99) | — | — | — |
| Month 4 | 39.2 (1.0 to 63.0) | — | — | — |
Quantitative analysis of high-intensity proMBP-positive basophil-like cells in FFPE blood leukocyte pellet sections.
| Cells per section | Group 1: T2-high Asthma Initiating Mepolizumab | Group 2: T2-high Asthma on Maintenance Mepolizumab | Group 3: Moderate-severe Asthma Not Eligible for Biologics | Group 4: Healthy Controls |
|---|---|---|---|---|
| Baseline | 52.8 (12 to 125) | — | — | — |
| Day 2 | 17.8 (2 to 62) | — | — | — |
| Month 4 | 19.8 (5 to 45) | — | — | — |
Relative proportion of low-/mid-intensity proMBP-positive eosinophil-lineage proxy cells within the proMBP panel in FFPE blood leukocyte pellet sections
| Proportion of proMBP panel | Group 1: T2-high Asthma Initiating Mepolizumab | Group 2: T2-high Asthma on Maintenance Mepolizumab | Group 3: Moderate-severe Asthma Not Eligible for Biologics | Group 4: Healthy Controls |
|---|---|---|---|---|
| Baseline | 0.0318 (0.0087 to 0.0514) | — | — | — |
| Day 2 | 0.0339 (0.0044 to 0.0649) | — | — | — |
| Month 4 | 0.0118 (0.0013 to 0.0252) | — | — | — |
Quantitative CD4 Th-axis balance readout in FFPE blood leukocyte pellet sections, expressed as log2(GATA3/T-bet ratio).
| log2 ratio | Group 1: T2-high Asthma Initiating Mepolizumab | Group 2: T2-high Asthma on Maintenance Mepolizumab | Group 3: Moderate-severe Asthma Not Eligible for Biologics | Group 4: Healthy Controls |
|---|---|---|---|---|
| Baseline | 2.946 (1.802 to 6.147) | — | — | — |
| Day 2 | 0.862 (-0.168 to 2.422) | — | — | — |
| Month 4 | 2.075 (0.000 to 4.621) | — | — | — |
Quantitative B-cell HLA-DR readout in FFPE blood leukocyte pellet sections, expressed as the percentage of HLA-DR-positive cells within the CD19/CD20-gated population.
| Percent of CD19/CD20-gated cells | Group 1: T2-high Asthma Initiating Mepolizumab | Group 2: T2-high Asthma on Maintenance Mepolizumab | Group 3: Moderate-severe Asthma Not Eligible for Biologics | Group 4: Healthy Controls |
|---|---|---|---|---|
| Baseline | 61.857 (50.909 to 69.643) | — | — | — |
| Day 2 | 42.465 (12.560 to 65.217) | — | — | — |
| Month 4 | 25.132 (3.774 to 47.826) | — | — | — |
Routine clinical laboratory total leukocyte counts in peripheral blood
| 10^9 cells/L | Group 1: T2-high Asthma Initiating Mepolizumab | Group 2: T2-high Asthma on Maintenance Mepolizumab | Group 3: Moderate-severe Asthma Not Eligible for Biologics | Group 4: Healthy Controls |
|---|---|---|---|---|
| Baseline | 8.16 (6 to 10.9) | — | — | — |
| Day 2 | 7.56 (5.2 to 10.6) | — | — | — |
| Month 4 | 8.52 (5.1 to 11.4) | — | — | — |
Spirometry: Forced Expiratory Volume, 1s; (FEV1).
Results for this outcome have not been posted.
Spirometry: Forced Vital Capacity (FVC)
Results for this outcome have not been posted.
Fractional exhaled NO will be measured at multiple flows
Results for this outcome have not been posted.
Collected over From enrollment through Month 4 follow-up for Group 1; from enrollment through the 1-week post-refill follow-up for Group 2; and during the baseline study visit for Groups 3 and 4. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Group 1: T2-high Asthma Initiating Mepolizumab | 0/5 (0%) | 0/5 (0%) | 0/5 (0%) |
| Group 2: T2-high Asthma on Maintenance Mepolizumab | 0/10 (0%) | 0/10 (0%) | 0/10 (0%) |
| Group 3: Moderate-severe Asthma Not Eligible for Biologics | 0/11 (0%) | 0/11 (0%) | 0/11 (0%) |
| Group 4: Healthy Controls | 0/11 (0%) | 0/11 (0%) | 0/11 (0%) |
Baseline characteristics were summarized across four observational study groups: T2-high asthma patients initiating mepolizumab, T2-high asthma patients on maintenance mepolizumab, severe asthma patients not eligible for biologics, and healthy controls.
| Age, Continuous(Years) | Group 1: T2-high Asthma Initiating Mepolizumab | Group 2: T2-high Asthma on Maintenance Mepolizumab | Group 3: Moderate-severe Asthma Not Eligible for Biologics | Group 4: Healthy Controls | Total |
|---|---|---|---|---|---|
| Median | 62 (40 to 74) | 69 (61 to 76) | 51 (38 to 67) | 47 (40 to 54) | 57 (38 to 76) |
| Sex: Female, Male(Participants) | Group 1: T2-high Asthma Initiating Mepolizumab | Group 2: T2-high Asthma on Maintenance Mepolizumab | Group 3: Moderate-severe Asthma Not Eligible for Biologics | Group 4: Healthy Controls | Total |
|---|---|---|---|---|---|
| Female | 3 | 5 | 9 | 9 | 26 |
| Male | 2 | 5 | 2 | 2 | 11 |
| Race and Ethnicity Not Collected(Participants) | Group 1: T2-high Asthma Initiating Mepolizumab | Group 2: T2-high Asthma on Maintenance Mepolizumab | Group 3: Moderate-severe Asthma Not Eligible for Biologics | Group 4: Healthy Controls | Total |
|---|---|---|---|---|---|
| Count of participants | — | — | — | — | 0 |
| BMI(kg/m2) | Group 1: T2-high Asthma Initiating Mepolizumab | Group 2: T2-high Asthma on Maintenance Mepolizumab | Group 3: Moderate-severe Asthma Not Eligible for Biologics | Group 4: Healthy Controls | Total |
|---|---|---|---|---|---|
| Median | 26.6 (24.3 to 30.8) | 28.3 (25.9 to 37.1) | 28.4 (22.4 to 32.9) | 23.8 (20.7 to 26.5) | 26.8 (20.7 to 37.1) |
| FEV1 % predicted(Percent predicted) | Group 1: T2-high Asthma Initiating Mepolizumab | Group 2: T2-high Asthma on Maintenance Mepolizumab | Group 3: Moderate-severe Asthma Not Eligible for Biologics | Group 4: Healthy Controls | Total |
|---|---|---|---|---|---|
| Median | 76 (52 to 85) | 66 (54 to 84) | 84 (69 to 91) | 101 (92 to 107) | 82 (52 to 107) |
| FEV1/FVC(Ratio) | Group 1: T2-high Asthma Initiating Mepolizumab | Group 2: T2-high Asthma on Maintenance Mepolizumab | Group 3: Moderate-severe Asthma Not Eligible for Biologics | Group 4: Healthy Controls | Total |
|---|---|---|---|---|---|
| Median | 0.7 (0.59 to 0.83) | 0.58 (0.5 to 0.71) | 0.69 (0.57 to 0.81) | 0.75 (0.72 to 0.79) | 0.68 (0.5 to 0.83) |
| ACT score(points) | Group 1: T2-high Asthma Initiating Mepolizumab | Group 2: T2-high Asthma on Maintenance Mepolizumab | Group 3: Moderate-severe Asthma Not Eligible for Biologics | Group 4: Healthy Controls | Total |
|---|---|---|---|---|---|
| Median | 15 (10 to 20) | 21 (19 to 24) | 15 (14 to 21) | 25 (25 to 25) | 18 (10 to 25) |
| Smoking status(Participants) | Group 1: T2-high Asthma Initiating Mepolizumab | Group 2: T2-high Asthma on Maintenance Mepolizumab | Group 3: Moderate-severe Asthma Not Eligible for Biologics | Group 4: Healthy Controls | Total |
|---|---|---|---|---|---|
| Never | 3 | 4 | 6 | 10 | 23 |
| Former | 2 | 6 | 5 | 1 | 14 |
1 further baseline measures are reported on the registry.
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Jan 2019 to primary completion in Sep 2025, 80 months.
Results were first posted in Nov 2026, 1 year 2 months after primary completion.
Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 5, 2026: start Feb 2023 → Jan 2019, primary completion Apr 2024 → Sep 2025 and completion Dec 2024 → Dec 2025.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in May 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.